Drug Trial Radar · NCT06971380
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
May 15, 2028
Study completion May 15, 2030
Sponsor
- Lead sponsor
- Polina StepenskyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.
Conditions
- Multiple Myeloma, Refractory to Standard Treatment
- Multiple Myeloma, Relapsed
- Light Chain Amyloidosis
Interventions
HBI0101 CARTBiological
HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response to HBI0101 CARTTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah MO
Jerusalem, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.